293 related articles for article (PubMed ID: 19471894)
1. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Lim J; Kang JS; Park SK; Lee K; Kim JY; Kim YJ; Hong JT; Kim Y; Han SB
Int Immunopharmacol; 2009 Mar; 9(3):375-80. PubMed ID: 19105981
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of cytokine-induced killer cells against human lung cancer.
Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
6. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
[TBL] [Abstract][Full Text] [Related]
7. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells.
Wang P; Yu JP; Gao SY; An XM; Ren XB; Wang XG; Li WL
Cell Immunol; 2008; 253(1-2):59-65. PubMed ID: 18522858
[TBL] [Abstract][Full Text] [Related]
8. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
9. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
10. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
11. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice.
Wongkajornsilp A; Somchitprasert T; Butraporn R; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Maneechotesuwan K; Hongeng S
Cancer Invest; 2009 Feb; 27(2):140-8. PubMed ID: 19235585
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
13. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
[TBL] [Abstract][Full Text] [Related]
16. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo].
Ge W; Li CH; Zhang W; Han Q; Deng WM; Chen L; You SG; Zhao CH
Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):277-80. PubMed ID: 15182535
[TBL] [Abstract][Full Text] [Related]
17. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
18. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
19. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
